BAY 3283142 clinical trials

(22040 ALPINE 1) A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease

This study is testing a new medicine, BAY 3283142, for people with long-term kidney disease. We want to see if it helps reduce kidney damage by lowering a protein called albumin in your urine, compared to a dummy pill. It's a key step to finding better treatments.